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Abstract Retraction of mesenchymal stromal cells sup-
ports the invasion of colorectal cancer cells (CRC) into the
adjacent compartment. CRC-secreted 12(S)-HETE enhan-
ces the retraction of cancer-associated fibroblasts (CAFs)
and therefore, 12(S)-HETE may enforce invasivity of CRC.
Understanding the mechanisms of metastatic CRC is cru-
cial for successful intervention. Therefore, we studied pro-
invasive contributions of stromal cells in physiologically
relevant three-dimensional in vitro assays consisting of
CRC spheroids, CAFs, extracellular matrix and endothelial
cells, as well as in reductionist models. In order to elucidate
how CAFs support CRC invasion, tumour spheroid-in-
duced CAF retraction and free intracellular Ca2? levels
were measured and pharmacological- or siRNA-based
inhibition of selected signalling cascades was performed.
CRC spheroids caused the retraction of CAFs, generating
entry gates in the adjacent surrogate stroma. The respon-
sible trigger factor 12(S)-HETE provoked a signal, which
was transduced by PLC, IP3, free intracellular Ca2?, Ca2?-
calmodulin-kinase-II, RHO/ROCK and MYLK which led
to the activation of myosin light chain 2, and subsequent
CAF mobility. RHO activity was observed downstream as
well as upstream of Ca2? release. Thus, Ca2? signalling
served as central signal amplifier. Treatment with the FDA-
approved drugs carbamazepine, cinnarizine, nifedipine and
bepridil HCl, which reportedly interfere with cellular cal-
cium availability, inhibited CAF-retraction. The
elucidation of signalling pathways and identification of
approved inhibitory drugs warrant development of inter-
vention strategies targeting tumour–stroma interaction.
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BEC Blood endothelial cell
CamK-II Ca2?-calmodulin kinase II
CRC Colorectal cancer
CCID Circular chemorepellent-induced defect
CAF Cancer-associated fibroblast
EC Endothelial cell
HLF Human lung fibroblast
IP3 Inositol-3-phosphate
MLC2 Myosin light chain 2
MMP1 Matrix metallo-protease 1
MYLK Myosin light chain kinase
PLC Phospholipase C
RHO Ras homologue gene family member
ROCK Rho-associated protein kinase
siRNA Small interfering RNA
3D 3-Dimensional
12(S)-HETE 12(S) hydroxyeicosatetraenoic acid
Introduction
The risk to develop colorectal cancer (CRC) is high and the
danger to die from metastases is evident. The multistage
nature of CRC development [1, 2] defines a number of
tumour suppressor genes and (proto)-oncogenes that
become de-regulated (i.e. by mutations, epigenetic modu-
lation of gene expression, or other), and once gene
expression changes in a certain spatio-temporal order the
cancer progresses stepwise in the well-known sequence:
aberrant crypt foci—adenoma—primary cancer—metasta-
sising carcinoma with the tumour leaving the hitherto
defined area. The vast mechanistic complexity of meta-
static spreading involves the dissolution of the basement
membrane, invasion into the surrounding stroma, intrava-
sation into blood and lymphatic vessels, circulation and
survival in these vessels, extravasation and eventually
colonialisation of a distant secondary site. The tumour–
stroma is critically involved in these processes and there is
compelling evidence for a cancer-associated fibroblast
(CAF) gene signature as adverse prognostic marker in CRC
[3, 4]. Thus, CRC needs the cooperation of stromal cells to
facilitate metastatic dissemination, yet the mechanisms are
poorly understood. A suspect pro-metastatic factor, which
is secreted by tumour cells and that takes on control over
stromal endothelial cells, is 12(S)-HETE. This pro-in-
flammatory arachidonic acid metabolite perturbs inter-
cellular junctions [5] and causes the retraction of lymphatic
and blood endothelial cell walls. Therefore, 12(S)-HETE is
called ‘‘endothelial retraction factor’’ [6] and may facilitate
CRC intravasation and lymph node metastasis [7]. Further,
12(S)-HETE, which is metabolised by the lipoxygenases
ALOX12 and ALOX15 [8] and by cytochrome-P450-1A1
(CYP1A1) [9, 10], induces the metastatic spreading of
prostate carcinoma cells [11]. 12(S)-HETE levels are not
significantly different in the tissue specimen of normal,
polyp and cancer mucosa [12], which is in accordance with
similar ALOX12 expression in normal glandular colon
cells and CRC tissue as detected by immunohistochemistry
(http://www.proteinatlas.org). However, the CRC cell lines
Caco2, SW480 and SW620 express steadily increasing
levels of ALOX12 and secrete increasing amounts of
12(S)-HETE, respectively, and this is directly proportional
to their metastasising potential i.e. increased growth in soft
agar and enhanced migration [13]. In line with this
observation, CYP1A1 mRNA is over-expressed in CRC
liver metastases as compared to normal colonic epithelium,
as detected by RNASeq, whereas CYP1A1 mRNA and
protein expression does not vary, between normal colonic
tissue and CRC. Hence, there may exist a direct correlation
between 12(S)-HETE production and metastatic spreading.
This is further supported by the finding that 12(S)-HETE
activates the pro-metastatic transcription factor ZEB1 in
endothelial cells, assisting the formation of cancer spher-
oid-triggered ‘‘circular chemorepellent induced defects’’
(CCIDs) [14], which resemble entry gates for the tumour
into the vasculature [15]. Conversely, the inhibition of ZEB
family expression by miR200 in endothelial cells reduces
their potential to form CCIDs [7]. Taken together there is
ample evidence that 12(S)-HETE and the ZEB pathway
contribute to malignancy and therefore, studying the
interface between cancer cells and their immediate stromal
environment is relevant to understand tumour spreading.
In the lymph node metastases of breast cancer patients,
the production of 12(S)-HETE correlates directly with
increased ALOX15 expression and inversely with metas-
tasis-free survival. Moreover, high ALOX12 expression in
the lymph node metastases of breast cancer patients
inversely correlates with metastasis-free survival as well
[15]. The contribution of ALOX15 to lymph node metas-
tases was furthermore proven in SCID mice, which were
orthotopically transgrafted with MCF-7 cells in which
ALOX15 [the major 12(S)-HETE producing enzyme in this
cell line] was knocked-down [15].
Physiologically, neutrophils and activated macrophages
secrete 12(S)-HETE, which causes endothelial barrier
retraction and enables their transmigration through the
vasculature to reach sites of inflammation [5, 16]. Appar-
ently, cancer cells can co-opt this property as cancer cell-
secreted 12(S)-HETE activates MLC2 in lymph endothelial
cells as a prerequisite for endothelial junction retraction
and formation of CCIDs [5, 17–19].
Here, we highlighted the role of 12(S)-HETE and the
response of CAFs in this inter-cellular communication and
tried to adapt a 3D intravasation model, to study mecha-
nisms of 12(S)-HETE-triggered CRC spheroid invasion
into the CAF compartment. We demonstrate that CAFs
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retract from CRC cell spheroids and form CCIDs and
identified signalling pathways that steer this process.
Materials and methods
Antibodies and reagents
Polyclonal rabbit anti-phospho-myosin light chain 2 (Ser19)
and polyclonal rabbit anti-myosin light chain 2 were pur-
chased from Cell Signaling (Danvers, MA, USA),
monoclonal mouse anti-MYLK was from Santa Cruz
Biotechnology (Heidelberg, Germany), polyclonal rabbit
anti-BLT2 antibody was from Sigma (Munich, Germany),
polyclonal rabbit anti-12(L)-HETE antibody (L-configura-
tion is identical to S-configuration for 12-HETE) from Enzo
Life Sciences (Lausen, Switzerland), monoclonal mouse
anti-cytokeratin-20 (CK20) antibody from Neomarker
(Thermo Fisher Scientific, Inc., Waltham, MA, USA),
monoclonal mouse anti-tenascin C antibody from Novo-
castra (Thermo Fisher Scientific, Inc., Waltham,MA, USA),
and polyclonal rabbit anti-GAPDH was from Trevigen
(Gaithersburg, MD, USA). Polyclonal swine anti-rabbit IgG
was purchased from Dako (Glostrup, Denmark) and poly-
clonal Alexa 488 goat anti-mouse and Alexa 594 goat anti-
rabbit antibodies were purchased from Molecular Probes
(Thermo Fisher Scientific, Inc., Waltham, MA, USA).
siRNAs targeting MLC2 (MYL2; SMART pool, ON-
TARGET PLUS, Cat. No.: L-011087000005) and MYLK
(SMART pool, ON-TARGET PLUS, Cat. No.:
L-0053510000) were ordered from Dharmacon (Gene
Expression and Gene Editing, GE Healthcare, Lafayette,
CO, USA), and non-targeting control siRNA (Silencer
Select Negative Control No. 1 siRNA, Cat. No.: 4390843)
was from Ambion (Life Technologies, Carlsbad, CA,
USA).
Baicalein, BAPTA-AM, edelfosine, KN-62 and Y27632
were purchased from Sigma Aldrich (Munich, Germany),
blebbistatin, U73122 and rhosin were from Calbiochem
(Merck Millipore, Darmstadt, Germany), bepridil
hydrochloride (B5016), cinnarizine (C5270), carba-
mazepine (C8981) and nifedipine (N7634) from Sigma
Aldrich (Munich, Germany). 12(S)-HETE was purchased
from Cayman Chemical (Ann Arbor, MI, USA), and cell-
tracker Green CMFDA Dye and cell-tracker Red CMTPX
Dye were ordered from Invitrogen (Karlsruhe, Germany).
Cell culture
Human SW620 (CCL-227, lymph node metastasis) and
SW480 (CCL-228, primary tumour) colorectal adenocar-
cinoma cells were obtained from American Type Culture
Collection (ATCC, Rockville, MD, USA) and grown in
RPMI or DMEM, respectively, supplemented with 10%
foetal calf serum (FCS), 1% penicillin/streptomycin (PS),
and L-glutamine. Human colon adenoma cells, LT-97 [20],
were cultivated in WNRE medium [RPMI/10% FCS sup-
plemented with conditioned medium of L cells producing
recombinant WNT3A, Noggin and R-spondin (10% each)
supplemented with human recombinant EGF (50 ng/ml,
PeproRech)]. Human Lung Fibroblasts (HLFs, CCL-135)
were purchased from American Type Culture Collection
(ATCC, Rockville, MD, USA) and maintained in DMEM
supplemented with 10% FCS, 1% PS and 1% L-glutamine.
Human primary CAF (CT5.3) were isolated from a col-
orectal adenocarcinoma resection specimen obtained in
accordance with the local ethics committee (Ghent
University Hospital). In short, tissue fragments were cut in
small pieces and transferred into a six-well plate with FCS.
Isolated CT5.3 were infected with a pBABE retroviral
vector expressing the hTERT open reading frame [21].
CT5.3 cells were cultivated in DMEM supplemented
with 10% FCS, 1% PS, and 1% L-glutamine and 2 lg/ml
puromycin. Primary CAFs (CAF3) [22] and human dermal
microvascular endothelial cells (BECs; C-12260, Promo-
cell, Heidelberg, Germany) were maintained in EGM2 MV
(Clonetics CC-4147, Allendale, NJ, USA). All cells were
kept at 37 C in a humidified atmosphere containing 5%
CO2.
Spheroid formation
SW480 cells (1500 cells per spheroid) or SW620 cells (2000
cells per spheroid) were transferred into DMEM (supple-
mented with 5% FCS, 1% PS and 1% L-glutamine)
containing methylcellulose (M-512; Sigma Aldrich) at a
final concentration of 0.3%. 150 ll of this cell suspension
was transferred to each well of a 96-well round bottom plate
(Greiner Bio-one, Cellstar 650185, Kremsmu¨nster, Austria).
The plates were centrifuged for 30 min at 1000 rpm and
thereafter incubated for 4 days to allow spheroid formation.
LT-97 cells (2000 cells per spheroid) were transferred
into WNRE medium without methylcellulose and 150 ll of
this cell suspension seeded into each well of a 96-well,
non-adhesive, round bottom plate (Nunclon Sphera ULA
plates). The plates were centrifuged for 30 min at
1000 rpm and thereafter incubated for 4 days to allow
spheroid formation.
Colon cancer invasion model (collagen gel culture)
Nylon meshes were prepared from nylon mesh inserts of
Medicon syringe filters (100 lm, Becton–Dickinson) of
which a hole of 1 cm diameter was cut out in the centre.
The nylon meshes were autoclaved and placed onto the
inside surface of lids of 24-well plates. CT5.3 cells were
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stained with cell-tracker green (Invitrogen, Karlsruhe,
Germany), trypsinised and counted. A total of 4 9 105
cells for each gel were transferred into 1.5-ml Eppendorf
tubes and centrifuged at 1000 rpm for 5 min at 4 C. For
collagen gel preparation, all steps were performed on ice.
Collagen solutions were prepared by mixing 2 mg/ml
collagen I (Corning, collagen I, rat tail, Bedford, MA,
USA), 10% 109 PBS and DMEM and were neutralised by
the addition of 7 ll/ml 1 M NaOH. A total of 300 ll each
of the collagen solution was transferred into the tubes
containing the cell pellets which were gently re-suspended.
The collagen/cell suspensions were carefully transferred on
the nylon meshes and incubated for 30 min at 37 C/5%
CO2 to allow the collagen solutions to solidify. Thereafter,
1 ml DMEM was added into each well and gels were
incubated for 24 h. Then, BECs were stained with cell-
tracker red, trypsinised and counted. 2 9 105 cells were
transferred on top of each collagen gel and the co-cultures
were incubated for another 24 h. SW620 spheroids were
prepared as described above, washed and carefully placed
on top of the BEC monolayer. 24 h after spheroid transfer,
CCID areas in BECs and CAFs were analysed using a
fluorescence microscope.
Circular chemo-repellent-induced defect (CCID)
assay
In this assay, the sizes of cell free areas (circular chemo-
repellent induced defects; CCIDs) which are formed in the
CAF monolayer directly underneath the tumour spheroids
were measured. Primary CAFs, CT5.3 cells or HLFs were
grown to confluence in 24-well plates and subsequently
stained with cell-tracker green. Colon cancer spheroids
were washed with PBS and transferred on top of the CAF
or HLF monolayers. After 6 h of co-cultivation, CCID
areas were photographed using an Axiovert (Zeiss, Jena,
Germany) fluorescence microscope to visualise the cell-
tracker stained CAFs or HLFs. CCID areas were calculated
using Zen Little 2012 software (Zeiss, Jena, Germany). For
each condition, the CCID areas of at least 15 spheroids
were measured.
Transfection of primary CAFs and CT5.3 cells
Cells were seeded in 24-well plates and grown to 70%
confluence. A total of 0.75 lg siRNA and 4 ll HiPerFect
Transfection Reagent (QIAGEN, Cat. No.: 301705) were
mixed in 100 ll serum-free medium and incubated for
30 min at room temperature to allow the formation of
transfection complexes, which were then carefully added
onto the cells (to a final siRNA concentration of 100 nM).
The cells were incubated for 48 h at normal growth
conditions and were subsequently used for CCID assays or
RNA isolation.
Quantitative RT-PCR (qPCR)
Cells were harvested after transfection, and RNA was
isolated using the RNeasy Mini Kit 50 and QIAshredder 50
(QUIAGEN, Hamburg, Germany). The final RNA con-
centration was measured using a NanoDrop
Fluorospectrometer (Thermo Fisher Scientific, Inc., Wal-
tham, MA, USA). An amount of 2 lg of total RNA was
reverse transcribed using RNA to cDNA EcoDry Premix
Protocol-At-A-Glance (Clontech, 2 Saint-Germain-en-
Laye, France). The resulting cDNA was amplified using
TaqMan Gene Expression Master Mix (Applied Biosys-
tems, Vienna, Austria). The PCR products were analysed
on the Chromo4 PCR System (Bio-Rad, Hercules, CA,
USA). The following TagMan probes were used: GAPDH
(Hs99999905_m1) and MYLK (Hs00364926_ma). qPCR
was performed in triplicate for each cDNA template. Gene
expression was normalised to GAPDH expression (glyc-
eraldehyde 3-phosphate dehydrogenase) and was
calculated using the DDCT method.
SDS gel electrophoresis and Western blotting
CT5.3 cells were grown in T-25 tissue culture flasks (Nunc,
Roskilde, Denmark) or six-well plates to 80% confluence
and subsequently starved for 24 h. Then, cells were pre-
treated with respective inhibitors or solvent for 1 h and
stimulated with 1 lM 12(S)-HETE for another 15 min.
Afterwards, cells were washed twice with ice-cold PBS and
lysed in buffer containing 50 mM Tris–HCl (pH 6.8), 6%
SDS, 20% glycerine, 1.85 mM EDTA, phosphatase inhi-
bitor cocktail, and protease inhibitor cocktail. For complete
cell lysis, the mixture was sonicated 5–10 times on ice. The
lysate was stored at -20 C until further analysis. Equal
amounts of protein were separated by SDS polyacrylamide
gel electrophoresis and electro-transferred onto Amersham
Hybond-P PVDF transfer membrane (GE Healthcare,
Freiburg, Germany) at 100 V for 1 h in ice-cold transfer
buffer [containing 20 mM Tris-base, 150 mM glycine,
20% (v/v) methanol, pH 8.5]. Membranes were stained
with Ponceau S (Sigma-Aldrich, Munich, Germany) to
control transfer efficiency and equal sample loading. After
washing with TBS-T (Tris Buffered Saline/Tween 20; pH
7.6), membranes were immersed in blocking solution (5%
non-fat dry milk in TBS containing 0.1% Tween20) at
room temperature for 1 h. Then, membranes were washed
and incubated with primary antibodies (5% BSA in TBS-T;
1:500–1:1000) by gently rocking at 4 C overnight.
Thereafter, membranes were washed and incubated with
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secondary antibodies (peroxidase-conjugated swine anti-
rabbit IgG, dilution 1:5000) at room temperature for 1 h.
Chemo-luminescence was developed by Amersham ECL
prime Kit (GE Healthcare, Freiburg, Germany) and
detected using a Lumi-Imager F1 Workstation (Roche,
Basel, Switzerland). Densitometry of Western blots was
analysed with Image-J software (National Institutes of
Health, Maryland, USA).
Immunofluorescence
Fresh unfixed human tissue was stored in nitrogen and
sectioned in 3-lm-thick slices using a Cryostar NX50
(Thermo Fisher Scientific, Inc., Waltham, MA, USA).
Sections were then transferred on Superfrost-Plus object
slides (Thermo Fisher Scientific, Inc., Waltham, MA,
USA) and dried for 10 min at room temperature (RT).
Then samples were incubated with primary antibodies
(1:50 in Tris buffer pH 7.2) for 30 min at RT. After
washing three times with Tris buffer, samples were incu-
bated with secondary antibodies for another 30 min at RT.
Then, slides were washed again and incubated with DAPI
(1:50,000) for 1 min. Thereafter, samples were embedded
with GelTol, coverslipped and analysed on a Zeiss LSM5-
Exiter confocal microscope (Zeiss, Jena, Germany). Sur-
gical specimens were collected from three patients who
underwent surgery for colorectal cancer and gave their
informed consent. The study protocol was approved by the
ethics committee of the Medical University of Vienna (EK
1659/2012).
Intracellular Ca21 assay
Free intracellular Ca2? levels were measured using Fluo-
Forte Calcium Assay Kit (Enzo Life Science, Ann Abor,
MI, USA). 3 9 104 CT5.3 cells/well/100 ll DMEM were
seeded into 96-well black-wall clear-bottom plates (Nunc,
Thermo Scientific, NY, USA). After 24 h, cells were pre-
treated with respective inhibitors or solvent for 1 h and
subsequently incubated in 100 ll FluoForte Dye for
45 min at 37 C and 15 min at room temperature. Then,
cells were stimulated with 1 lM 12(S)-HETE and fluo-
rescence was measured at 490/525 nm using a fluorescence
plate reader.
12(S)-HETE assay
DLD-1 and SW620 cells were seed in six-well plates and
grown in 2.5 ml complete MEM medium to *70–80
confluence when FCS was removed overnight. Then, cells
were treated with 10 lM arachidonic acid (Sigma-Aldrich,
Munich, Germany) in serum-free medium for another 4 h.
The concentration of 12(S)-HETE in the cellular
supernatant was measured with minor modifications as
described previously [23] using the 12(S)-HETE enzyme
immunoassay kit (Enzo Life Sciences, Lausen, Switzer-
land). Absorbance was measured with a Wallac 1420
Victor 2 multilabel plate reader (Perkin Elmer Life and
Analytical Sciences, Shelton, CT, USA). The concentration
of 12(S)-HETE in the cellular supernatant was normalsed
to cell number to account for differences in the cell
number.
Statistical analysis
For statistical analyses, Excel 2013 software and Prism 6
software package (GraphPad, San Diego, CA, USA) were
used. The values were expressed as mean ± SEM and one-
way ANOVA and student’s t test was applied to compare
differences between control samples and treatment groups.
Statistical significance level was set to p\ 0.05.
Results
Establishment of a 3D in vitro model resembling
CRC invasion into stroma
It was shown that cancer cells repel endothelial cells [15],
and here we investigated whether fibroblasts may as well
retract from CRC spheroids. SW620 spheroids were placed
on top of immortalised CT5.3 CAFs [21], which induced
their retraction within 6 h thereby forming CCIDs
(Fig. 1a). In patients, the stroma around CRC mucosa often
consists of densely packed fibroblasts. Therefore, CT5.3
CAFs were cultivated more densely and also under these
conditions CAFs were forced by SW620 spheroids to
retract, although the CCID areas were smaller than in less
densely grown CAFs (Fig. 1b; in order to better distinguish
individual fibroblasts in this setting 50% of CT5.3 were
stained with cell-tracker red and 50% with cell-tracker
green). Also, primary CAFs (CAF3) [22] responded with
retraction when SW620 spheroids were placed on top
(Fig. 1c). Furthermore, SW480 spheroids (SW480 is the
primary tumour of the matching SW620 lymph node
metastasis)-induced CCIDs in CT5.3 cell layers, which
demonstrates the potential also of the primary tumour to
invade the surrounding stroma (Fig. 1d). In contrary, non-
cancerous LT-97 adenoma cells [20] did not trigger CCID
formation in the CAF barrier within 6 h (Fig. 1d). To stress
the model further, CAFs were covered with collagen I,
which mimics the stroma/matrix histopathology surround-
ing CRCs. Then, SW620 spheroids were placed on top,
which still caused the retraction of CT5.3 cells thereby
establishing a cell-free area (not shown). In addition, blood
endothelial cells (BECs) were included to this model and
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seeded onto the surface of collagen I-embedded CAFs. On
top of this co-culture system, SW620 spheroids were
placed. Under these conditions, the spheroids induced the
formation of CCIDs in BECs and also the retraction of the
subjacent fibroblasts (Fig. 1e). The setting of this in vitro
model closely resembles the patho-physiology in humans
when CRC cells extravasate the blood vasculature and
invade a distant organ. Metastatic CRC especially invades
liver and lungs. Indeed, SW620 spheroids caused also the
retraction of normal human lung fibroblasts (HLFs) even if
these cells were less responsive when compared with CAFs
(Fig. 1f). Therefore, the phenomenon of CCID formation is
not restricted to colon CAFs as also EC junction retraction
was due to CRC-secreted 12(S)-HETE [7]. To localise
12(S)-HETE in human normal and cancerous colonic
epithelia, fresh cryo-preserved and non-fixed tumour tis-
sues were analysed by immunofluorescence and laser
scanning microscopy. In normal as well as in cancerous
colonic mucosa cells, 12(S)-HETE was detected (Supple-
mentary Fig. S1). A quantification by this method was not
possible, as the harsh conditions of the colon environment
certainly degraded most of the 12(S)-HETE molecule
(which is rapidly oxidised at four different double bonds
etc.), but in general, these data are in agreement with
HPLC data, which demonstrate that normal colon-, polyp-
and colon cancer mucosa produce similar amounts of
12(S)-HETE [12]. The level of the 12(S)-HETE concen-
tration in metastases of CRC remains unexplored, since
metastases are not surgically removed in the clinical rou-
tine. To this end, it is of particular interest that RNA
sequencing revealed CYP1A1 mRNA over-expression in
CRC liver metastases as compared to normal colonic
epithelium (http://www.ebi.ac.uk/gxa/experiments/E-
GEOD-50760?geneQuery=ENSG00000140465&query
FactorValues=g2_g1&_specific=on).
Given that CCID formation was demonstrated in all
variations of our experiments and that 12(S)-HETE was
detected in CRC tissue, the model was reduced in the next
step (as shown in Fig. 1a, c) to investigate the underlying
mechanism causing retraction.
12(S)-HETE-activated MLC2 triggers CCID
formation in the CRC-stroma invasion model
Metastatic SW620 cells were shown to express ALOX12
and to secrete 12(S)-HETE. SW480 and the well-differ-
entiated CaCo2 cells (both derived from primary tumour
sites) express less ALOX12 and produce only half the
amount of 12(S)-HETE as compared to SW620 cells [13].
Also, DLD-1 cells (derived from a primary tumour site)
secreted lower levels of 12(S)-HETE [7.3 ng/ml (23 nM)]
than metastatic SW620 cells [10.6 ng/ml (33 nM)] within
4 h (1 9 106 cells, each). This suggests a direct correlation
between higher 12(S)-HETE production and increasing
malignancy. However, this did not correlate with their
CCID-forming potential, as SW60 and SW480 spheroids
induced CCID formation alike (Fig. 1d) and this implicated
that both cell types may have produced an overload of
12(S)-HETE, which triggered maximal fibroblasts retrac-
tion. In the immediate proximity of CAFs, the
concentration of 12(S)-HETE that was secreted by SW620
spheroids must have been much higher than 33 nM at least
in the in vitro setting studied here. To confirm the contri-
bution of 12(S)-HETE upon SW620 spheroid-triggered
CCID formation within the CAF barrier, ALOX12, a major
producer of 12(S)-HETE, was inhibited by baicalein. In the
CRC/CAF invasion model using immortalised CT5.3
fibroblasts as well as primary CAF3, baicalein attenuated
the formation of CCIDs (Fig. 2a, b). Therefore, ALOX12
in SW620 cells, and consequently 12(S)-HETE, induced
CCID formation in CAF barriers similar to that induced in
EC barriers [7]. EC retraction and CCID formation depend
on the expression and activity of the mobility marker
myosin light chain 2 (MLC2) [24] and we hypothesised
that this might also be the case in CAFs. Indeed, the
treatment of CT5.3 cells with 0.25–2.0 lM (80–638 ng/ml)
12(S)-HETE triggered the phosphorylation of MLC2 at
serine 19, indicating its activation (Fig. 2c). Therefore,
CAFs were further on treated with a standardised concen-
tration of 1 lM 12(S)-HETE to study the mechanisms of
their retraction and CCID formation. MLC2 was essential
for CAF retraction, since siRNA-mediated knock-down of
MLC2 expression (siMLC2) reduced the CCID areas
(Fig. 2d; proper knock-down of MLC2 is shown in sup-
plementary Fig. S2). Inhibition of MLC2 activity by
blebbistatin (Fig. 2e) significantly inhibited CCID forma-
tion in the CAF barrier as well, which further substantiated
the contribution of MLC2 to CAF retraction.
bFig. 1 Colon cancer spheroid-induced CCID formation in CAFs
SW620 spheroids was transferred on a cell-tracker (green) stained
CT5.3 or b more densely seeded CT5.3 (50% of CT5.3 were stained
with green cell-tracker the other 50% were stained with red cell-
tracker) or c on cell-tracker (green) stained primary CAF3 layers. The
formation of CCIDs was monitored at different time points by
fluorescence microscopy. The formation of CCIDs was monitored at
different time points by fluorescence microscopy. Representative
pictures of at least three independent experiments are shown.
d Quantification of SW620, SW480 and LT-97 induced CCID
formation in CT5.3 monolayers. e Collagen gel culture of CT5.3 cells,
BECs and SW620 spheroids. Cell-tracker (green) stained CT5.3 cells
were embedded in collagen I gel. Then, cell-tracker (red) stained
BECs were seeded on top of these gels. Subsequently, SW620
spheroids were placed on top and the formation of CCIDs was
monitored after 24 h by fluorescence microscopy. Cultures without
SW620 spheroids were used as controls (small inset). f Quantification
of SW620 spheroid-induced CCID formation in CT5.3 and HLF
monolayers. Scale bars 200 lm. Bar graphs represent means, error
bars indicate ± SEM, asterisks significance compared to control
(p\ 0.05; t test or ANOVA)
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12(S)-HETE-triggered Ca21 release induces MLC2
activation and CCID formation
12(S)-HETE induces Ca2? release in normal human
fibroblasts [25], HEK239 cells [26] and in CHO cells
through the BLT2 low affinity receptor [27], and was
reported to activate L-type calcium channels in renal
myocytes [28]. BLT2 is expressed in the colon cancer-
associated fibroblasts, CT5.3, as well (Supplementary
Fig. S3) and accordingly, Ca2? levels increased
Fig. 2 CCID formation in
CT5.3 and CAF3 is inhibited by
baicalein and depends on
MLC2. SW620 spheroids were
pre-treated with baicalein at
indicated concentrations or
solvent (control; DMSO) and
transferred on cell-tracker
stained a CT5.3 or b CAF3
monolayers. After 6 h CCID
areas were measured. c CT5.3
cells were stimulated with 0.25,
0.5, 1.0, 1.5 and 2.0 lM 12(S)-
HETE or solvent (0) for 20 min.
Western blotting was used to
determine MLC2
phosphorylation at serine 19.
Equal sample loading was
controlled by MLC2 total
protein and GAPDH. Phospho-
MLC2 (p-MLC2) was
quantified by densitometry and
normalised to MLC2 and
GAPDH. Solvent treated control
was set to 1. d CT5.3 cells were
transfected with either non-
targeting RNA (NTC) or siRNA
targeting MLC2 (siMLC2).
After 24 h SW620 spheroids
were transferred on top of the
CT5.3 monolayers and after 6 h
co-cultivation CCID areas were
measured. e CT5.3 cells were
pre-treated with blebbistatin at
indicated concentrations or
solvent control (control;
DMSO). Then, SW620
spheroids were placed on top of
the CT5.3 cell monolayers for
6 h and CCID areas were
measured. Bar graphs represent
means, error bars indicate ±
SEM, asterisks significance
compared to control (p\ 0.05;
t test)
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significantly in 12(S)-HETE-treated CT5.3 cells (Fig. 3a).
The co-treatment with the specific intracellular Ca2?
chelator BAPTA-AM evidenced that Ca2? signalling was
responsible for 12(S)-HETE-induced Ser19-MLC2 phos-
phorylation (Fig. 3b) and furthermore, BAPTA-AM
inhibited CRC-induced CCID formation in CT5.3 (Fig. 3c)
and CAF3 (Fig. 3d). The immediate upstream factor trig-
gering Ca2? release from intracellular stores is inositol-3-
phosphate (IP3) and the IP3-generating enzyme phospho-
lipase-C-beta (PLCb). Consistently, the inhibition of IP3
generation by U73122 significantly attenuated Ca2? release
(Fig. 3e) and CRC-triggered CCID formation (Fig. 3f) and
the PLC inhibitor edelfosine attenuated the retraction of
CT5.3 cells as well (Fig. 3g). In addition, both inhibitors,
U73122 and edelfosine, inhibited the phosphorylation of
MLC2 (Supplementary Fig. S4). Therefore, the PLCb–
IP3–Ca2?–MLC2 pathway is critically involved in 12(S)-
HETE-induced CCID formation in CAFs.
ROCK transduces 12(S)-HETE-triggered MLC2
activation and CCID formation
Next, we addressed how increased cellular Ca2? levels
may induce CAF retraction. Ca2? activates Ca-calmodulin
kinase II (CamK-II) and specific inhibition of CamK-II by
treatment of CAFs with KN-62 significantly attenuated
CCID formation (Fig. 4a) and MLC2 phosphorylation
(Supplementary Fig. S4). In dendritic cells, CamK-II
activates the RHO/ROCK axis, both are regulators of cel-
lular mobility, thereby linking Ca2? signalling to cell
movement [29]. Here we demonstrate that this was also the
case in CT5.3 fibroblasts, as treatment with the ROCK-
inhibitor Y27632 attenuated 12(S)-HETE-induced MLC2
phosphorylation at Ser19 (Fig. 4b). Furthermore, CRC-
triggered CCID formation was inhibited by Y27632 in
CT5.3 (Fig. 4c) and CAF3 (Fig. 4d) and by the RHO
inhibitor rhosin (Fig. 4e, f) in a dose-dependent manner,
which inhibited MLC2 phosphorylation (Supplementary
Fig. S4) as well. Therefore, the CamK-II/RHO/ROCK/
MLC2 pathway transduces the 12(S)-HETE signal in
CAFs, leading to retraction and opening the gate for
tumour invasion in vitro.
Interestingly, 12(S)-HETE-induced increase in free
intracellular Ca2? levels was inhibited by rhosin (Fig. 4g),
suggesting that RHO transduced signals not only down-
stream of CamK-II but also upstream of Ca2? release
thereby representing a kind of feedback loop. CamK-II was
reported to activate RHO [30, 31] and RHO induces PLC-
epsilon, Ca2? release, and cytoskeleton modifications
[32, 33]. Consistently, the inhibition of RHO together with
the inhibition of Ca2? release attenuated CCID formation
additively (Fig. 4h). Another Ca2?-calmodulin kinase
subtype, MYLK which activates MLC2 directly [34],
contributed to CCID formation as well. This was demon-
strated by siRNA-mediated depletion of MYLK in CT5.3
fibroblasts and CAF3, which attenuated CCID formation
(Fig. 4i, j; proper knock-down of MYLK expression is
shown in supplementary Fig. S5). Taken together, these
data place Ca2? as a central signal for retraction of CAFs
triggered by CRC spheroids.
FDA-approved pharmaceutical drugs inhibit 12(S)-
HETE-induced Ca21 release and CRC invasion
in vitro
To test the hypothesis that Ca2? signalling is pivotal for
CAF retraction, CT5.3 were pre-treated with FDA-ap-
proved drugs that reportedly influence Ca2? availability by
blocking respective ion channels. For this, we used car-
bamazepine (inhibiting L-type calcium channels),
cinnarizine (inhibiting IP3-induced intracellular Ca2?
mobilisation), nifedipine (inhibiting L-type calcium chan-
nels specifically on vascular cells) and bepridil
hydrochloride (inhibits binding to calmodulin only in the
presence of calcium, thereby inhibiting MYLK and MLC2
phosphorylation) [35–38]. Each of these drugs inhibited
Ca2? release (Fig. 5a), as well as phosphorylation of
MLC2 (except cinnarizine; Supplementary Fig. S4), and
significantly attenuated SW620-mediated CCID formation
in CT5.3 (Fig. 5b–e). Of note, in vitro retraction of CAFs
was reduced at drug concentrations that can be principally
achieved in humans.
Discussion
Over time, malignant cancer cells acquire pro-invasive
properties that are necessary to overcome a number of
obstacles posed by the surrounding environment and, as an
example, cancer cells reprogram their microenvironment to
achieve metastatic outgrowth. In short, metastatic spread-
ing involves remodelling of the basal matrix, local invasion
through the adjacent stroma, transmigration into blood and
lymph vessels, lymph node metastasis, mastering the shear
stress within blood and lymph vessels, extravasation, and
organ invasion. All these steps require a close cooperation
of the tumour microenvironment. Therefore, understanding
and manipulating of even just one of the many metastatic
steps may provide a rationale for the prevention and the
therapeutic management of metastasis. Yet, studies to
delineate the contribution of stromal cells in this process
mechanistically are scarce.
Honn and co-workers identified 12(S)-HETE as the
‘‘endothelial retraction factor’’ [6]. Neutrophils and
monocytes are known to secrete 12(S)-HETE [5, 39]
enabling them to transmigrate through endothelial cell
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(EC) barriers by triggering EC junction retraction. Like-
wise, MCF-7 breast cancer- [16, 40] and SW620 CRC cells
[13] co-opt this mechanism and secrete 12(S)-HETE,
which facilitates entering the lymphatic vasculature, trav-
elling through the lymphatic endothelium and colonising
lymph nodes. Baicalein is an accepted bona fide inhibitor
of ALOX12/15, yet not entirely specific. Thus, the pro-
duction of 12(S)-HETE by ALOX12/15 and its role for EC
junction retraction and CCID formation was not only
examined upon treatment with baicalein but also by an
approach using shRNA against ALOX15 and the correla-
tion between both inhibition experiments was direct and
strict in a breast cancer/EC model [15]. As baicalein
inhibited the retraction phenotype also in CRC/EC
intravasation models [7, 15], it was also applied in the
CRC/CAF model to highlight a role of ALOX12/15 in the
invasion of CRC. CYP1A1 is another enzyme that pro-
duces 12(S)-HETE. CYP1A1 inhibition by siRNA and
proadifen in breast cancer cells [10] or by proadifen in
CRC cells [7] reduced the synthesis of 12(S)-HETE and the
formation of CCIDs in EC monolayers as well and thus,
further supports a role of 12(S)-HETE in the malignancy of
CRC. Evidence for the pro-invasive contribution of 12(S)-
HETE is provided by a CRC in vivo model in which the
double amount of ALOX12-overexpressing SW480 cells
[secreting four to fivefold more 12(S)-HETE as compared
to control cells] [41] were detected in the vicinity of the
lung blood vessels after transgrafting them into the rear
flank of SCID mice [13]. ECs and CAFs are of mes-
enchymal origin and therefore quite mobile. 12(S)-HETE
even increases their mesenchymal signature, which is
reminiscent to ‘‘endothelial-to-mesenchymal-transition’’
(Endo-MT) in ECs [7, 14]. 12(S)-HETE also enhances the
invasion of prostate cancer cells [42] potentially involving
‘‘epithelial-to-mesenchymal-transition’’ (EMT). Here, we
elucidated the molecular/biochemical and cellular response
of CAFs to CRC-derived 12(S)-HETE and demonstrate for
the first time that 12(S)-HETE forced CAF retraction
in vitro, which resulted in the formation of large gaps and
upon contact with CRC spheroids both cell types dispersed
into each other. It has to be underscored that the molecular
adhesion between cancer cells and CAFs is an absolute
prerequisite for CCID formation. However, the protago-
nists of inter-cellular adhesion are not yet identified in the
here presented 3D model. Whether NF-kB and ICAM-1
establish CRC-CAF adhesion, as shown to be the case in
12(S)-HETE-triggered breast cancer/EC intravasation
[14, 19], needs to be investigated in future studies.
We provide mechanistic evidence that the 12(S)-HETE-
triggered signal in CAFs was mediated at least in part by
the Ca2?/RHO/ROCK signalling axis ultimately leading to
MLC2 activation, as all tested signal transduction inhibi-
tors abrogated not only the 12(S)-HETE-induced signalling
cascade and MLC2 phosphorylation (except cinnarizine),
but also CCID formation. Most importantly, the knock-
down of MLC2 inhibited CRC-triggered CCID formation
in CAFs as well and this strongly argues for a contribution
of 12(S)-HETE in the disintegration of the CAF barrier.
MLC2 expression and activation are the driving com-
ponents of CAF mobility and cancer cell invasion. Also in
ECs 12(S)-HETE activates MLC2, which significantly
contributes to CCID formation [24, 43, 44]. Furthermore, it
was shown that activated MLC2 in breast cancer cells
accelerates their movement through the underlying
endothelium [45]. Hence, during tumour progression,
MLC2 seems to play a critical role in cancer cells and
adjacent stromal cells. This is in accordance with the
observation that tumour cell invasion is supported by the
increased mobility of all involved cell types, which start to
merge and mingle. However, the induction of MLC2
phosphorylation and CCID formation is not exclusively
caused by the 12(S)-HETE gradient, as there are also other
factors prompting tropism and retraction i.e. MMP1, which
induces Ca2? release and MLC2 activation in ECs as well
[19, 46]. Yet, treating the CRC/CAF model with the pan-
matrix metalloprotease inhibitor GM6001 did not inhibit
the formation of CCIDs (data not shown). Therefore, this
mechanism, which is known to contribute significantly in
breast cancer/EC models, was not active during invasion of
CRC into the CAF compartment.
Ca2? availability and release are crucial steps in medi-
ating retraction and mobility. Consistently, chelation of
Ca2? (by BAPTA-AM) together with simultaneous inhi-
bition of RHO (by rhosin) impaired CCID formation within
the CAF barrier, probably due to blocking the positive
feed-back loop of RHO on Ca2? release. Alternatively, the
reduced CCID formation may have been due to simulta-
neous blocking of MYLK (another Ca2?-calmodulin kinase
bFig. 3 Analysis of the 12(S)-HETE-induced Ca2? pathway in CT5.3
cells. a CT5.3 were pre-treated with 2.5 lM BAPTA-AM, 2.5 lM
U73122 or DMSO and subsequently incubated with FluoForteTM
Dye. Then, cells were stimulated with 1 lM 12(S)-HETE or solvent
(control; DMSO) and intracellular-free calcium was measured after
3 min. b CT5.3 were pre-treated with 2.5 lM BAPTA-AM or DMSO
and stimulated with 1 lM 12(S)-HETE or solvent (control; DMSO).
After 15-min cells were lysed, proteins separated by SDS gel
electrophoresis and analysed by Western blotting was used to
determine MLC2 phosphorylation at serine 19. Equal sample loading
was controlled by MLC2 total protein and GAPDH. Phospho-MLC2
(p-MLC2) was quantified by densitometry and normalised to MLC2
and GAPDH. Solvent-treated control was set to 1. c–f CAFs were pre-
treated with the intracellular Ca2? chelator BAPTA-AM, U73122
(inhibiting the generation of IP3) and the PLC inhibitor edelfosine at
indicated concentrations or DMSO (control). Then, SW620 spheroids
were placed on top of the CAF monolayers for 6 h and CCID areas
were measured. Bar graphs represent means, error bars indicate ±
SEM, asterisks significance compared to control (p\ 0.05; t test or
ANOVA)
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subtype directly activating MLC2) [34] together with the
inhibition of RHO. MYLK is strongly expressed in CAFs
as well as in IMR-90 normal lung fibroblasts (https://www.
ebi.ac.uk/gxa/home) and we could demonstrate that pri-
mary normal human lung fibroblasts (HLF) respond in a
similar way to SW620 spheroids as CAFs. Nearly as strong
as MYLK is the expression of CamK-IId in IMR-90
fibroblasts, whereas the expression of CamK-IIg, CamK-I
and CamK-III (EEF2K) is low (https://www.ebi.ac.uk/gxa/
home; E-GEOD-26284; EMBL-EBI Expression Atlas,
which contains gene expression data based on RNA
sequencing). Hence, all of these CamKs may have con-
tributed to the 12(S)-HETE-triggered and Ca2?-mediated
fibroblast response that resulted in MLC2 phosphorylation
and CCID formation. In line with the central role of ele-
vated Ca2? levels in response to 12(S)-HETE, we
demonstrate that clinically used drugs, which were chosen
on their property to affect calcium supply, inhibited the
invasion of CRC spheroids through the CAF barrier. Of
note, the here tested FDA-approved drugs diminished CAF
retraction at concentrations that can be reached in humans.
Therefore, it is tempting to speculate that interfering with
Ca2? availability might be a broadly applicable and
promising route to combat metastasis in the clinic. This
could be achieved in a short time frame, since such inhi-
bitors are already approved and in use. However, one
bFig. 4 RHO/ROCK signalling is involved in CAF retraction. a CT5.3
were pre-treated with the CamK-II inhibitor KN-62 at indicated
concentrations or solvent as control (control; DMSO). Subsequently,
SW620 spheroids were placed on top of the fibroblasts for 6 h CCID
areas were measured. b Cells were pre-treated with 2.5 lM of the
ROCK inhibitor Y27632 or solvent and subsequently stimulated with
1 lM 12(S)-HETE or solvent (control; DMSO) for 15 min. Western
blotting was used to determine MLC2 phosphorylation at serine 19.
Equal sample loading was controlled by MLC2 total protein and
GAPDH. Phospho-MLC2 (p-MLC2) was quantified by densitometry
and normalised to MLC2 and GAPDH. Solvent treated control was
set to 1. c–f CT5.3 and CAF3 were pre-treated with Y27632 and the
RHO inhibitor rhosin at indicated concentrations or solvent as control
(control; DMSO). Subsequently, SW620 spheroids were placed on
top of the fibroblasts for 6 h CCID areas were measured. g CT5.3
were pre-treated with 20 lM rhosin or DMSO, stimulated with 1 lM
12(S)-HETE or solvent (control; DMSO) and intracellular-free
calcium was measured after 3 min. h CT5.3 cells were pre-treated
with 20 lM rhosin, 1 lM BAPTA-AM or both and solvent (DMSO)
was used as control (control). Then, SW620 spheroids were placed on
top of CT5.3 for 6 h and CCID areas were measured. i, j CT5.3 and
CAF3 were transfected with either non-targeting RNA (NTC) or
siRNA targeting MYLK (siMYLK). After 24 h SW620 spheroids
were transferred on top of the CT5.3 monolayers and after 6 h co-
cultivation CCID areas were measured. Error bars indicate mean ± -
SEM, asterisks significance compared to control or compared to the
experimental points connected by brackets (p\ 0.05; t test or
ANOVA)
Fig. 5 Inhibition of intracellular Ca2? level increase and CCID
formation by FDA-approved drugs. a CT5.3 were pre-treated with
either carbamazepine, cinnarizine, nifedipine, bepridil hydrochloride
or DMSO, stimulated with 1 lM 12(S)-HETE or solvent (control;
DMSO) and intracellular-free calcium was measured after 3 min. b–
e CT5.3 cells were pre-treated with either carbamazepine, cinnarizine,
nifedipine and bepridil hydrochloride at indicated concentrations or
solvent (control; DMSO). Then, SW620 spheroids were placed on top
of the CT5.3 for 6 h and CCID areas were measured. Bar graphs
represent means, error bars indicate ± SEM, asterisks significance
compared to control (p\ 0.05; t test or ANOVA)
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should have in mind that cancer cells may co-opt any
mechanism (not just the one described herein) that has
evolved to disintegrate, repulse and penetrate foreign tissue
types.
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